# A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

> **NCT02837991** · PHASE1 · TERMINATED · sponsor: **Celldex Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Clear-cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Kidney Neoplasms
- Metastatic Renal Cell Carcinoma
- Ovarian Clear Cell Carcinoma

## Interventions

- **DRUG:** CDX-014

## Key facts

- **NCT ID:** NCT02837991
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2018-11-16
- **Final completion:** 2018-11-16
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Development of CDX-014 discontinued
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02837991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02837991, "A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02837991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*